PNC Financial Services Group’s KalVista Pharmaceuticals KALV Stock Holding History

PNC Financial Services Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-149	Closed	-$3K	–	5291
2026 Q1	$3K	Buy	149 +3	+2%	+$48	﹤0.01%	4459
2025 Q4	$2.36K	Sell	146 -27	-16%	-$358	﹤0.01%	4489
2025 Q3	$2.11K	Sell	173 -351	-67%	-$4.85K	﹤0.01%	4486
2025 Q2	$5.92K	Buy	524 +387	+282%	+$4.73K	﹤0.01%	4064
2025 Q1	$1.58K	Buy	137 +118	+621%	+$1.2K	﹤0.01%	4408
2024 Q4	$161	Hold	19	–	–	﹤0.01%	4670
2024 Q3	$220	Hold	19	–	–	﹤0.01%	4672
2024 Q2	$224	Buy	+19	New	+$222	﹤0.01%	4650
2024 Q1	–	Sell	-5	Closed	-$61	–	4758
2023 Q4	$61	Buy	+5	New	+$45	﹤0.01%	4545
2021 Q3	–	Sell	-59	Closed	-$1K	–	4356
2021 Q2	$1K	Buy	+59	New	+$1.54K	﹤0.01%	4123

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PNC Financial Services Group's KALV Position: Q2 2026 in Review

PNC Financial Services Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 149 shares — an estimated $3K sold.

PNC Financial Services Group first reported a position in KALV in Q2 2021 and held it in 10 quarters. The position peaked at $5.92K in Q2 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

PNC Financial Services Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
PNC Financial Services Group sold 149 KalVista Pharmaceuticals shares in Q2 2026, an estimated $3K.
PNC Financial Services Group first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 10 quarters.
PNC Financial Services Group's KalVista Pharmaceuticals position peaked at $5.92K in Q2 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.